The 4th World Symposium on Pulmonary Hypertension

An increase in the number of therapeutic strategies brings new opportunities but also new challenges. [...]there is a need for well-designed clinical trials with appropriate end points that will enable reliable interpretation of the benefit-to-risk profile of all current and emerging therapies. [......

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 54; no. 1; pp. S1 - S2
Main Authors Humbert, Marc, MD, PhD, McLaughlin, Vallerie V., MD
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 30.06.2009
Elsevier Limited
Subjects
Cardiology
Cardiovascular
Clinical trials
Disease
Drug therapy
Internal Medicine
Meetings
Mutation
Pulmonary arteries
Pulmonary hypertension
Online AccessGet full text

Cover

More Information
Summary:An increase in the number of therapeutic strategies brings new opportunities but also new challenges. [...]there is a need for well-designed clinical trials with appropriate end points that will enable reliable interpretation of the benefit-to-risk profile of all current and emerging therapies. [...]1 working group dedicated itself to an in-depth examination of the benefits and drawbacks of a variety of clinical trial end points and designs to determine the most interpretable and clinically relevant.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2009.04.013